Compare Biogen Inc (BIIB) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Endeavour Silver Corp — how do they compare? Biogen Inc trades at $206.92 (market cap $30.13B), while Endeavour Silver Corp trades at $10.62 (market cap $3.14B). The key difference: Biogen Inc is far larger — about 9.6× Endeavour Silver Corp's market cap, and Biogen Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| BIIB | EXK | |
|---|---|---|
Market Cap | $30.13B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $14.12 |
52-Week Low | $128.93 | $5.31 |
Enterprise Value | $37.20B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Endeavour Silver (EXK) trades at $10.68, up 4.3% today, with a bullish technical outlook driven by moving averages and strong analyst sentiment. The company reported Q2 2026 earnings in line with estimates at $0.15 per share, with revenue growth and operational execution highlighted in recent news. Financials show improving trends, with 2026 revenue projected at $737 million and net income turning positive to $66 million, though 2025 saw a net loss of $119 million. A new $25 million credit facility was secured in August 2026, supporting liquidity.
The stock offers upside to the consensus price target of $15.50, with 79% of analysts rating it Buy. Key risks include volatile silver prices, execution challenges at new mines, and high valuation multiples like a P/E of 52.95. Positive catalysts include production ramp-ups and favorable metal price outlooks, but investors should monitor debt levels and commodity cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
